Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

33 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Autoimmune bullous dermatoses in cancer patients treated by immunotherapy: a literature review and Italian multicentric experience.
Merli M, Accorinti M, Romagnuolo M, Marzano A, Di Zenzo G, Moro F, Antiga E, Maglie R, Cozzani E, Parodi A, Gasparini G, Sollena P, De Simone C, Caproni M, Pisano L, Fattore D, Balestri R, Sena P, Vezzoli P, Teoli M, Ardigò M, Vassallo C, Michelerio A, Satta RR, Dika E, Melotti B, Ribero S, Quaglino P. Merli M, et al. Among authors: fattore d. Front Med (Lausanne). 2023 Jul 20;10:1208418. doi: 10.3389/fmed.2023.1208418. eCollection 2023. Front Med (Lausanne). 2023. PMID: 37547602 Free PMC article.
Vitiligo-like lesions in patients with advanced breast cancer treated with cycline-dependent kinases 4 and 6 inhibitors.
Sollena P, Nikolaou V, Soupos N, Kotteas E, Voudouri D, Stratigos AJ, Fattore D, Annunziata MC, Orlandi A, Di Nardo L, Apalla Z, Deilhes F, Romano MC, Fabbrocini G, Sibaud V, Peris K; European Network for Cutaneous ADverse event of Oncologic drugs (ENCADO) group. Sollena P, et al. Among authors: fattore d. Breast Cancer Res Treat. 2021 Jan;185(1):247-253. doi: 10.1007/s10549-020-05914-w. Epub 2020 Sep 10. Breast Cancer Res Treat. 2021. PMID: 32914354
Clinical associations and classification of immune checkpoint inhibitor-induced cutaneous toxicities: a multicentre study from the European Academy of Dermatology and Venereology Task Force of Dermatology for Cancer Patients.
Nikolaou VA, Apalla Z, Carrera C, Fattore D, Sollena P, Riganti J, Segura S, Freites-Martinez A, Lallas K, Romano MC, Oikonomou C, Starace M, Dimopoulos MA, Kyrgidis A, Lazaridou E, Giavedoni P, Annunziata MC, Peris K, Echeverría M, Lopez-Tujillo E, Syrigos K, Papageorgiou C, Podlipnik S, Fabbrocini G, Torre AC, Kemanetzi C, Villa-Crespo L, Lallas A, Stratigos AJ, Sibaud V. Nikolaou VA, et al. Among authors: fattore d. Br J Dermatol. 2022 Dec;187(6):962-969. doi: 10.1111/bjd.21781. Epub 2022 Sep 6. Br J Dermatol. 2022. PMID: 35861701
Clinical characterization and treatment outcomes of follicular cutaneous immune-related adverse events caused by immune checkpoint inhibitors: A multicenter retrospective study.
Freites-Martinez A, Nikolaou V, Lallas K, Carrera C, Sollena P, Apalla Z, Starace M, Fattore D, Fabbrocini G, Segura S, Riganti J, Sibaud V. Freites-Martinez A, et al. Among authors: fattore d. J Am Acad Dermatol. 2023 Mar;88(3):718-720. doi: 10.1016/j.jaad.2022.08.063. Epub 2022 Sep 22. J Am Acad Dermatol. 2023. PMID: 36152697 No abstract available.
The urgent need of dermatologists for cancer patients in Italy.
Fattore D, Fabbrocini G, Sibaud V, Sollena P. Fattore D, et al. Ital J Dermatol Venerol. 2023 Jun;158(3):274-275. doi: 10.23736/S2784-8671.23.07531-X. Epub 2023 May 10. Ital J Dermatol Venerol. 2023. PMID: 37162245 No abstract available.
Cyclin-Dependent Kinase 4/6 Inhibitors and Dermatologic Adverse Events: Results from the EADV Task Force "Dermatology for Cancer Patients" International Study.
Sollena P, Vasiliki N, Kotteas E, Stratigos AJ, Fattore D, Orlandi A, Mannino M, Di Pumpo M, Fida M, Starace M, Apalla Z, Romano MC, Riganti J, Segura S, Martinez AF, Fabbrocini G, Sibaud V, Peris K, On Behalf Of The Eadv Task Force Dermatology For Cancer Patients. Sollena P, et al. Among authors: fattore d. Cancers (Basel). 2023 Jul 18;15(14):3658. doi: 10.3390/cancers15143658. Cancers (Basel). 2023. PMID: 37509319 Free PMC article.
Immune checkpoint-mediated psoriasis: A multicenter European study of 115 patients from the European Network for Cutaneous Adverse Event to Oncologic Drugs (ENCADO) group.
Nikolaou V, Sibaud V, Fattore D, Sollena P, Ortiz-Brugués A, Giacchero D, Romano MC, Riganti J, Lallas K, Peris K, Voudouri D, Lallas A, Fabbrocini G, Lazaridou E, Carrera C, Annunziata MC, Rossi E, Patri A, Rigopoulos D, Stratigos AJ, Apalla Z. Nikolaou V, et al. Among authors: fattore d. J Am Acad Dermatol. 2021 May;84(5):1310-1320. doi: 10.1016/j.jaad.2020.08.137. Epub 2020 Dec 3. J Am Acad Dermatol. 2021. PMID: 33279646
European recommendations for management of immune checkpoint inhibitors-derived dermatologic adverse events. The EADV task force 'Dermatology for cancer patients' position statement.
Apalla Z, Nikolaou V, Fattore D, Fabbrocini G, Freites-Martinez A, Sollena P, Lacouture M, Kraehenbuehl L, Stratigos A, Peris K, Lazaridou E, Richert B, Vigarios E, Riganti J, Baroudjian B, Filoni A, Dodiuk-Gad R, Lebbé C, Sibaud V. Apalla Z, et al. Among authors: fattore d. J Eur Acad Dermatol Venereol. 2022 Mar;36(3):332-350. doi: 10.1111/jdv.17855. Epub 2021 Dec 15. J Eur Acad Dermatol Venereol. 2022. PMID: 34910332
Autoimmune Skin Diseases and Immune Checkpoint Inhibitors.
Fattore D, Potestio L, Genco L, Pages C, Ortiz A, Fabbrocini G, Sibaud V. Fattore D, et al. Crit Rev Immunol. 2022;42(3):11-22. doi: 10.1615/CritRevImmunol.2023047032. Crit Rev Immunol. 2022. PMID: 37017623 Review.
33 results